NYMX: Nymox Pharmaceutical Corporation - Summary | Jitta

Nymox Pharmaceutical Corporation

NASDAQ:NYMX

Notice
Stock data is unavailable or the company’s delisted.
Price
$0.07
Loss Chance
58.0%
1.03JITTA SCORE
100.00%Over Jitta Line
Jitta Ranking
Sorry, the data is not yet available for this stock.
HISTORICAL JITTA SCORE
Jitta Factors
Growth Opportunity (24)
Recent Business Performance (42)
Financial Strength (36)
Return to Shareholders (0)
Competitive Advantage (14)
Jitta Signs
Recent Business PerformanceEarning Growth Last Year
Cash Conversion CycleLess than 30 days
Operating MarginInconsistent
CapExVery High
Key Stats
Jitta Score
Jitta Line
1.03
100.00%
2.21
145.02%
3.06
207.06%
Biotechnology
6.24
33.66%
6.13
8.74%
6.36
42.84%
COMPANY DESCRIPTION
Nymox Pharmaceutical Corporation, a biopharmaceutical company, engages in the research and development of drugs for the aging population in Canada, the United States, Europe, and internationally. Its lead drug candidate is Fexapotide Triflutate (NX-1207), which is in various clinical trials for the treatment of benign prostatic hyperplasia and low grade localized prostate cancer, as well as is in preclinical studies for hepatocellular carcinoma. The company also develops and markets NicAlert for detecting tobacco product usage; and TobacAlert for detecting second-hand smoke exposure. In addition, it develops drugs for the treatment of Alzheimer’s disease. Nymox Pharmaceutical Corporation was founded in 1989 and is headquartered in Nassau, the Bahamas.